Patents Assigned to EDUSA Pharmaceuticals, Inc.
  • Publication number: 20110294881
    Abstract: A method is provided for using ?2? subunit calcium channel modulators or other compounds that interact with the ?2? calcium channel subunit in combination with one or more compounds with smooth muscle modulatory effects to treat and/or alleviate the symptoms associated with painful and non-painful lower urinary tract disorders in normal and spinal cord injured patients. According to the present invention, ?2? subunit calcium channel modulators include GABA analogs (e.g. gabapentin and pregabalin), fused bicyclic or tricyclic amino acid analogs of gabapentin, and amino acid compounds. Compounds with smooth muscle modulatory effects include antimuscarinics, ?3 adrenergic agonists, spasmolytics, neurokinin receptor antagonists, bradykinin receptor antagonists, and nitric oxide donors.
    Type: Application
    Filed: August 9, 2011
    Publication date: December 1, 2011
    Applicant: EDUSA PHARMACEUTICALS, INC.
    Inventors: Matthew Oliver Fraser, Karl Bruce Thor, Edward C. Burgard, Lee R. Brettman, Steven B. Landau, Daniel J. Ricca
  • Publication number: 20110275667
    Abstract: The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount is from about one to about three daily doses of the compound and the dose is from about 0.2 mg to about 0.5 mg.
    Type: Application
    Filed: July 19, 2011
    Publication date: November 10, 2011
    Applicant: EDUSA Pharmaceuticals, Inc.
    Inventors: Suhail Nurbhai, Steven B. Landau
  • Publication number: 20110269792
    Abstract: The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof.
    Type: Application
    Filed: July 11, 2011
    Publication date: November 3, 2011
    Applicant: EDUSA Pharmaceuticals, Inc.
    Inventors: Steven B. Landau, Suhail Nurbhai
  • Publication number: 20100247584
    Abstract: The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount is from about one to about three daily doses of the compound and the dose is from about 0.2 mg to about 0.5 mg.
    Type: Application
    Filed: April 1, 2010
    Publication date: September 30, 2010
    Applicant: EDUSA Pharmaceuticals, Inc.
    Inventors: Suhail Nurbhai, Steven B. Landau